openPR Logo
Press release

Diffuse Intrinsic Pontine Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

06-27-2024 09:20 PM CET | Health & Medicine

Press release from: ABNewswire

Diffuse Intrinsic Pontine Glioma Pipeline 2024 | FDA Approvals,

DelveInsight's, "Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Diffuse Intrinsic Pontine Glioma Research. Learn more about our innovative pipeline today! @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook [https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report

* June 2024:- Nationwide Children's Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
* June 2024:- Pfizer- A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1).
* DelveInsight's Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
* The leading Diffuse Intrinsic Pontine Glioma Companies such as Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
* Promising Diffuse Intrinsic Pontine Glioma Therapies such as Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.

Stay informed about the cutting-edge advancements in Diffuse Intrinsic Pontine Glioma Treatments. Download for updates and be a part of the revolution in disease care @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile

* MTX 110: Midatech

MTX110 is a watersoluble form of panobinostat free base, achieved through complexation with hydroxypropyl cyclodextrin (HPBCD) that enables convectionenhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a nonselective histone deacetylase inhibitor (panHDAC inhibitor). Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma. MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the bloodbrain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimizing systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patientderived DIPG cell lines.

* Paxalisib: Kazia Therapeutics

Paxalisib (originally GDC-0084) was invented by Genentech, Inc (South San Francisco, CA), the most successful developer of new cancer medicines in the world. Kazia entered into a worldwide exclusive license agreement with Genentech in October 2016. Genentech designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The distinguishing feature of paxalisib is its ability to cross the blood-brain barrier (BBB). Ordinarily, the BBB prevents many drugs from reaching brain tissue, and is a challenge in the treatment of any disease in the central nervous system. Paxalisib has been designed to cross the BBB, and a wealth of experimental data shows that it does so very successfully. This feature of paxalisib is almost unique in this class of medicines and differentiates it from the approved products in the PI3K inhibitor class.

Learn more about Diffuse Intrinsic Pontine Glioma Drugs opportunities in our groundbreaking H Diffuse Intrinsic Pontine Glioma Research and development projects @ Diffuse Intrinsic Pontine Glioma Unmet Needs [https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Discover the latest advancements in Diffuse Intrinsic Pontine Glioma Treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report

* Coverage- Global
* Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation
* Diffuse Intrinsic Pontine Glioma Therapies- Everolimus, ONC201, AloCELYVIR, Ribociclib, Everolimus, Palbociclib, Temozolomide, Irinotecan, and others.
* Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Diffuse Intrinsic Pontine Glioma Pipeline on our website @ Diffuse Intrinsic Pontine Glioma Drugs and Companies [https://www.delveinsight.com/sample-request/diffuse-intrinsic-pontine-glioma-dipg-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Diffuse Intrinsic Pontine Glioma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Diffuse Intrinsic Pontine Glioma- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase I/II)
* MTX 110: Midatech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name : Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Diffuse Intrinsic Pontine Glioma Key Companies
* Diffuse Intrinsic Pontine Glioma Key Products
* Diffuse Intrinsic Pontine Glioma- Unmet Needs
* Diffuse Intrinsic Pontine Glioma- Market Drivers and Barriers
* Diffuse Intrinsic Pontine Glioma- Future Perspectives and Conclusion
* Diffuse Intrinsic Pontine Glioma Analyst Views
* Diffuse Intrinsic Pontine Glioma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diffuse-intrinsic-pontine-glioma-pipeline-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diffuse Intrinsic Pontine Glioma Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight here

News-ID: 3557371 • Views:

More Releases from ABNewswire

Superior Replacement Windows Awarded
Superior Replacement Windows Awarded "Best in Phoenix" for Premium Auto Glass Se …
Superior Replacement Windows continues to set the standard for luxury vehicle windshield replacement in Phoenix, combining family-owned customer service with specialized expertise in high-end automotive glass services. The company's "Best in Phoenix" recognition reinforces their position as the preferred choice for owners of luxury sedans, exotic sports cars, supercars, and electric vehicles throughout Arizona. Superior Replacement Windows, a locally owned and operated Phoenix windshield replacement company serving Maricopa County since 2010,
Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data Loss, Maximum Speed, Enterprise Peace of Mind
Apps4.Pro Migration Manager Transforms Microsoft 365 Tenant Migration: Zero Data …
Tirunelveli, India - 30 August, 2025 - When global enterprises need to migrate their Microsoft 365 environments, failure isn't an option. A single misstep can mean lost data, broken workflows, and frustrated teams. Today, Apps4.Pro-trusted by over 15,000 organizations worldwide-announces the enhanced Migration Manager platform that's redefining what's possible in tenant-to-tenant migration. From Fortune 500 giants like Siemens Energy and Johnson & Johnson to fast-scaling startups, organizations are discovering a migration
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs Increase Insurance Risks
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs I …
Brandon, FL - Homeowners in Brandon, Florida, are facing increased pressure to replace aging roofs as insurance companies tighten coverage requirements. Dynamic Roofing Concepts provides roof replacement in Brandon, FL [https://www.dynamicroofingconcepts.com/] and has seen increased demand as local homeowners face pressure from insurance companies to replace aging roofs. In Florida, most homeowners are aware that old roofs are more vulnerable to wind and water damage. Insurance providers have responded by requiring
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert Guide for Austin, TX
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential. Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that

All 5 Releases


More Releases for Diffuse

Diffuse Large B-cell Lymphoma Therapeutics: A Leading Driver Behind Rising Preva …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Diffuse Large B-cell Lymphoma Therapeutics Industry Market Size Be by 2025? The market for therapeutics used in the treatment of diffuse large B-cell lymphoma has seen significant growth in recent times. The market size is projected to expand from $4.74 billion in 2024 to $5.15 billion
Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment Report 2024 (Upda …
DelveInsight's, "Diffuse Large B-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
Diffuse Large B-cell Lymphoma Pipeline Drugs Report 2024 (Updated) | DelveInsigh …
DelveInsight's, "Diffuse Large B-Cell Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in
Global Diffuse Sensors Market Analysis By Manufacturers and Competitive landscap …
Diffuse photoelectric sensor means that when the transmitter emits a beam, the target will produce diffuse reflection, and the transmitter and receiver form a standard component that will change the state of the switch when enough combined light is returned to the receiver. Diffuse Sensors report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Diffuse Sensors market is projected to reach US$ 777.7
Diffuse-reflective Photoelectric Sensors Market Size, Share, Development by 2024
LP INFORMATION offers a latest published report on Diffuse-reflective Photoelectric Sensors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Diffuse-reflective Photoelectric Sensors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019.
Diffuse Large B-Cell Lymphoma Market Report 2017 Analysis & Research
Diffuse Large B-Cell Lymphoma Market: Overview With a noticeable rise in the prevalence of diffuse large B-cell lymphoma (DLBCL), the market for DLBCL market is witnessing strong growth across the world. Analysts expect the trend to remain so over the next few years, owing to the increasing number of elderly people, the most prone to DLBCL segment of the overall population. Diffuse large B-cell lymphoma (DLBCL) is the most common